Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.
With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
The machinery that governs gene expression is being targeted to beat cancer.
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
If the disease is in the lungs, why deliver the drugs everywhere else?
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
